A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

NCT02565914 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
1131
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Vertex Pharmaceuticals Incorporated